Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease - Summary - MDSpire
Advertisement
Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease
To evaluate the prognostic value of pan-immune-inflammation value (PIV) for major adverse cardiovascular and cerebrovascular events (MACCE) post-PCI in diabetics with coronary heart disease (CHD) and compare it to other inflammation-based markers.
Approach:
Study Design: Retrospective analysis of diabetic CHD patients undergoing PCI, calculating PIV from pre-procedural blood.
Patient Stratification: Patients were stratified into high/low PIV groups based on optimal cutoff determined via ROC curve.
Outcome Assessment: Follow-up for MACCE (e.g., MI, stroke, revascularization) using Kaplan–Meier survival, Cox regression, and ROC comparisons.
Key Findings:
Over a 24-month median follow-up, 52 MACCE occurred (24.8%).
The high-PIV group had a higher incidence of MACCE (37.7% vs. 11.5%, p < 0.001).
High PIV was confirmed as an independent predictor of MACCE (adjusted HR = 2.87, 95% CI: 1.55–5.32, p = 0.001).
PIV AUC = 0.74, outperforming SII (0.69), NLR (0.66), and PLR (0.64; DeLong's test p < 0.05 vs. NLR/PLR).
Interpretation:
PIV is a robust, independent predictor of MACCE post-PCI in diabetics, demonstrating superior accuracy over other markers.
Limitations:
Retrospective design.
Need for prospective validation.
Conclusion:
PIV may serve as a simple and cost-effective biomarker for individualized risk stratification in diabetic patients undergoing PCI.
